
St. Jude Medical
Investments
13Portfolio Exits
3Partners & Customers
10Service Providers
1About St. Jude Medical
St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological, and chronic pain patients worldwide.

Want to inform investors similar to St. Jude Medical about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Expert Collections containing St. Jude Medical
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find St. Jude Medical in 2 Expert Collections, including Medical Devices.
Medical Devices
3,383 items
Companies that received PMA from the FDA since 2014. Companies tagged as #FDAPMA
Digital Health
13,069 items
Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)
Latest St. Jude Medical News
Jan 27, 2023
Major Players Boston Scientific Corporation, Medtronic, Edwards Lifesciences Corporation, Abbott Laboratories, ST. JUDE MEDICAL, Biomerics, Comed BV, LivaNova PLC, JenaValve Technology Inc., and CardioKinetix. among others Segmentation Analysis Aortic valvular disease is expected to be the fastest-growing segment in 2022. The indication segment is divided into atrial septal defects, aortic valvular disease, pulmonary valvular disease, patent foramen ovale, ventricular septal defects, mitral valvular disease, patent ductus arteriosus, and others. The aortic valvular disease segment is expected to witness the highest growth rate during the forecast period. There is a connection between aortic valvular disease and the aorta, since the aorta carries oxygenated blood from the heart to the body, and when there is aortic valvular disease, the aorta does not fully open. In order to treat it, a structural cardiac device is implanted through minimally invasive surgical techniques. Therefore, the indication section will be dominated by aortic valvular disease. Heart valve devices are expected to be the fastest-growing segment in 2022. The product type segment is divided into heart valve devices, annuloplasty rings, occluders and delivery systems, transcatheter mitral valve repair, and others. The heart valve devices segment is expected to witness the highest growth rate during the forecast period. It is a one-way valve implanted into the heart as a replacement for a heart valve that does not function properly. A mechanical heart valve, a bioprosthetic tissue valve or an engineered tissue valve are three broad categories of artificial heart valves. Replacement is expected to be the fastest-growing segment in 2022. The procedure segment is divided into repair and replacements. The replacement segment is expected to witness the highest growth rate during the forecast period. As a result of the development of superior, flexible, sophisticated, resilient, and highly effective structural cardiac devices, the need for replacement has increased. A successful long-term alternative to repair methods is a replacement, which increases blood flow and makes the patient live a longer life. Regional Analysis The regional analysis provides a detailed perception of the key regions and the countries. Some of the key countries analyzed for the structural heart devices market include the US, Canada, Mexico, Germany, France, the U.K., Italy, Spain, Russia, China, Japan, India, Brazil, Peru, UAE, South Africa, and Saudi Arabia. The North American region witnessed a major share. Structural heart devices have been a major success in North America due to a large pool of patients, favourable reimbursement scenarios, and advanced healthcare infrastructure. Although minimally invasive surgery such as transcatheter aortic valve implantation (TAVI) and mitral valve repair/replacement may reduce utilization rates over the forecast period, increasing penetration may result in lower utilization rates. Country Analysis Germany Germany's structural heart devices market size was valued at USD 0.92 billion in 2022 and is expected to reach USD 2.18 billion by 2030, at a CAGR of 11.4% from 2023 to 2030. In Germany, the market is expanding due to an increase in surgeries, cardiovascular illnesses, and advanced treatment methods. China China’s structural heart devices market size was valued at USD 0.98 billion in 2022 and is expected to reach USD 2.37 billion by 2030, at a CAGR of 11.7% from 2023 to 2030. As awareness of cardiac disease increases, neonatal screening programs improve, and access to healthcare expands in China, the market is expected to expand. India India's structural heart devices market size was valued at USD 0.76 billion in 2022 and is expected to reach USD 1.8 billion by 2030, at a CAGR of 11.6% from 2023 to 2030. Increasing healthcare facility demand, a favourable reimbursement environment, and an increase in structural heart disease awareness drive the market for structural heart devices in the country. Covid-19 Impact Covid-19 had a major impact on almost all industries, such as electronics, semiconductors, manufacturing, automobile, etc. However, several companies operating in the technology sector have seen increased revenue due to significant changes in consumer preferences toward technological services. In addition, the pandemic has led to significant growth in technology across developing and developed countries. Furthermore, the growth of this market is mainly driven owing to the rising demand for flavored beverages among consumers, propelling the growth of the market across the countries. Buy Now Full Report @ https://greyviews.com/checkout/467/single_user_license Contact Us Browse Related Reports: Veterinary Hematology Analyzers Market Size By Product Type (Table Top Analyzers (Fully Automatic Analyzers and Semiautomatic Analyzers) and Point of Care Analyzers (Cartridge-Based Analyzers and Direct Sample Based Analyzers), By Analysis Parameter (2-Part WBC Differential, 3-Part WBC Differential, 5-Part WBC Differential, and Others), By End-User (Research institutes, Veterinary hospitals and clinics, Veterinary diagnostic centers, point-of-care testing, inhouse-testing, and others), Regions, Segmentation, and Projection till 2030 Structural Heart Devices Market Size By Indication (Atrial Septal Defects, Aortic Valvular Disease, Pulmonary Valvular Disease, Patent Foramen Ovale, Ventricular Septal Defects, Mitral Valvular Disease, Patent Ductus Arteriosus, and Others), By Product Type (Heart Valve Devices, Annuloplasty Rings, Occluders and Delivery Systems, Transcatheter Mitral Valve Repair, and Others), By Procedure(Repair and Replacements), Regions, Segmentation, and Projection till 2030 Shoulder Arthroplasty Market Size By Indication (Arthritis, Fracture/Dislocation, Rotator Cuff Tear Arthropathy, Hill Sachs Defect, and Others), By Device (Shoulder Arthroplasty Resurfacing Implants, Shoulder Arthroplasty Trauma Devices, and Shoulder Arthroplasty Platform Systems), By Procedure (Partial Shoulder Arthroplasty, Total Shoulder Arthroplasty, Reverse Shoulder Arthroplasty, and Revision Shoulder Arthroplasty), Regions, Segmentation, and Projection till 2030
St. Jude Medical Investments
13 Investments
St. Jude Medical has made 13 investments. Their latest investment was in Spinal Modulation as part of their Corporate Minority on June 6, 2013.

St. Jude Medical Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
6/11/2013 | Corporate Minority | Spinal Modulation | $40M | Yes | 2 | |
5/6/2011 | Series C | iRhythm Technologies | $15M | No | ||
9/17/2010 | Corporate Minority | CardioMems | $60M | No | 1 | |
5/21/2010 | Series B | |||||
5/19/2010 | Series G |
Date | 6/11/2013 | 5/6/2011 | 9/17/2010 | 5/21/2010 | 5/19/2010 |
---|---|---|---|---|---|
Round | Corporate Minority | Series C | Corporate Minority | Series B | Series G |
Company | Spinal Modulation | iRhythm Technologies | CardioMems | ||
Amount | $40M | $15M | $60M | ||
New? | Yes | No | No | ||
Co-Investors | |||||
Sources | 2 | 1 |
St. Jude Medical Portfolio Exits
3 Portfolio Exits
St. Jude Medical has 3 portfolio exits. Their latest portfolio exit was iRhythm Technologies on October 20, 2016.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
10/20/2016 | IPO | Public | 12 | ||
Date | 10/20/2016 | ||
---|---|---|---|
Exit | IPO | ||
Companies | |||
Valuation | |||
Acquirer | Public | ||
Sources | 12 |
St. Jude Medical Acquisitions
14 Acquisitions
St. Jude Medical acquired 14 companies. Their latest acquisition was Thoratec on July 22, 2015.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
7/22/2015 | Acq - P2P | 1 | ||||
4/20/2015 | Other | $106.9M | Acquired | 1 | ||
8/7/2014 | Acquired | 2 | ||||
6/2/2014 | Other | |||||
10/15/2013 | Series C |
Date | 7/22/2015 | 4/20/2015 | 8/7/2014 | 6/2/2014 | 10/15/2013 |
---|---|---|---|---|---|
Investment Stage | Other | Other | Series C | ||
Companies | |||||
Valuation | |||||
Total Funding | $106.9M | ||||
Note | Acq - P2P | Acquired | Acquired | ||
Sources | 1 | 1 | 2 |
St. Jude Medical Partners & Customers
10 Partners and customers
St. Jude Medical has 10 strategic partners and customers. St. Jude Medical recently partnered with Chalice Medical on October 10, 2021.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
10/12/2021 | Partner | United Kingdom | 1 | ||
9/27/2018 | Partner | Switzerland | World Health Organization, St. Jude Children's Research Hospital collaborate against childhood... MEMPHIS , Tenn. , Sept. 27 , 2018 / PRNewswire / -- St. Jude today announced a five-year collaboration with World Health Organization aimed at transforming cancer care worldwide to cure at least 60 percent of children with six of the most common types of cancer by 2030 . | 2 | |
6/5/2018 | Partner | United States | 1 | ||
12/18/2017 | Partner | ||||
11/21/2017 | Partner |
Date | 10/12/2021 | 9/27/2018 | 6/5/2018 | 12/18/2017 | 11/21/2017 |
---|---|---|---|---|---|
Type | Partner | Partner | Partner | Partner | Partner |
Business Partner | |||||
Country | United Kingdom | Switzerland | United States | ||
News Snippet | World Health Organization, St. Jude Children's Research Hospital collaborate against childhood... MEMPHIS , Tenn. , Sept. 27 , 2018 / PRNewswire / -- St. Jude today announced a five-year collaboration with World Health Organization aimed at transforming cancer care worldwide to cure at least 60 percent of children with six of the most common types of cancer by 2030 . | ||||
Sources | 1 | 2 | 1 |
St. Jude Medical Service Providers
1 Service Provider
St. Jude Medical has 1 service provider relationship
Service Provider | Associated Rounds | Provider Type | Service Type |
---|---|---|---|
Acq - P2P | Investment Bank | Sole Financial Advisor |
Service Provider | |
---|---|
Associated Rounds | Acq - P2P |
Provider Type | Investment Bank |
Service Type | Sole Financial Advisor |
Partnership data by VentureSource
St. Jude Medical Team
20 Team Members
St. Jude Medical has 20 team members, including , .
Name | Work History | Title | Status |
---|---|---|---|
Manny Villafaña | Founder | Current | |
Name | Manny Villafaña | ||||
---|---|---|---|---|---|
Work History | |||||
Title | Founder | ||||
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.